Kiniksa Pharmaceuticals International, plc (KNSA) FY2026 Q3 Balance Sheet

Published Source: Form 10-Q on SEC EDGAR filed (opens in a new tab)

As of 2026-09-30

Balance Sheet

Swipe to see the full flow
Kiniksa Pharmaceuticals International, plc (KNSA) FY2026 Q3 Balance SheetBalance sheet as of 2026-09-30. The chart shows assets, liabilities and equity at that date.Current liabilities$191.86 MLiabilities$273.05 MCurrent assets$750.10 MNon-current liabilities$81.20 MAssets$983.24 MEquity$710.19 MNon-current assets$233.14 MHOLDINGSASSET CLASSASSETSCLAIM CLASSCLAIM SUB-CLASSCLAIMSShort-term investmentsInventoryCash and cash equivalentsPrepaid expenses and other current assetsAccounts receivable, netDeferred tax assetsIntangible asset, netOther long-term assetsOperating lease right-of-use assetsProperty and equipment, netAccrued collaboration expensesAccrued expensesOther current liabilitiesAccounts payableOperating lease liabilitiesOther long-term liabilitiesNon-current deferred revenueNon-current operating lease liabilitiesAdditional paid-in capitalOrdinary shares value - Class A ordinary sharesOrdinary shares value - Class A1 ordinary sharesOrdinary shares value - Class B1 ordinary sharesOrdinary shares value - Class B ordinary sharesAccumulated deficitAccumulated other comprehensive lossCurrent assetsNon-current assetsAssetsCurrent liabilitiesNon-current liabilitiesLiabilitiesEquityEquityAccrued collaboration expensesAccrued collaboration expenses$105.82 MCurrent liabilitiesCurrent liabilities$191.86 MAccrued expensesAccrued expenses$57.70 MOther current liabilitiesOther current liabilities$20.26 MAccounts payableAccounts payable$4.11 MLiabilitiesLiabilities$273.05 MShort-term investmentsShort-term investments$487.10 MCurrent assetsCurrent assets$750.10 MOperating lease liabilitiesOperating lease liabilities$3.97 MOther long-term liabilitiesOther long-term liabilities$45.47 MNon-current liabilitiesNon-current liabilities$81.20 MInventoryInventory$108.03 MNon-current deferred revenueNon-current deferred revenue$31.81 MAssetsAssets$983.24 MCash and cash equivalentsCash and cash equivalents$81.66 MNon-current operating lease liabilitiesNon-current operating lease liabilities$3.92 MPrepaid expenses and other current assetsPrepaid expenses and other current assets$42.53 MAccounts receivable, netAccounts receivable, net$30.78 MEquityEquity$710.19 MAdditional paid-in capitalAdditional paid-in capital$1.08 BDeferred tax assetsDeferred tax assets$198.04 MNon-current assetsNon-current assets$233.14 MIntangible asset, netIntangible asset, net$14.50 MOrdinary shares value - Class A ordinary sharesOrdinary shares value - Class A ordinary shares$12.00 KOther long-term assetsOther long-term assets$10.75 MOrdinary shares value - Class A1 ordinary sharesOrdinary shares value - Class A1 ordinary shares$4.00 KOperating lease right-of-use assetsOperating lease right-of-use assets$7.39 MOrdinary shares value - Class B1 ordinary sharesOrdinary shares value - Class B1 ordinary shares$4.00 KProperty and equipment, netProperty and equipment, net$2.46 MOrdinary shares value - Class B ordinary sharesOrdinary shares value - Class B ordinary shares$1.00 KAccumulated deficitAccumulated deficit−$366.77 MAccumulated other comprehensive lossOther comprehensive loss−$2.75 M
Chart details

Kiniksa Pharmaceuticals International, plc (KNSA) FY2026 Q3 Balance Sheet

Balance sheet as of 2026-09-30. The chart shows assets, liabilities and equity at that date.

Assets
983,243,000 US dollars
Current assets
750,099,000 US dollars
Non-current assets
233,144,000 US dollars
Liabilities
273,050,000 US dollars
Current liabilities
191,855,000 US dollars
Non-current liabilities
81,195,000 US dollars
Equity
710,193,000 US dollars
Short-term investments
487,098,000 US dollars
Inventory
108,028,000 US dollars
Cash and cash equivalents
81,660,000 US dollars
Prepaid expenses and other current assets
42,534,000 US dollars
Accounts receivable, net
30,779,000 US dollars
Deferred tax assets
198,042,000 US dollars
Intangible asset, net
14,500,000 US dollars
Other long-term assets
10,749,000 US dollars
Operating lease right-of-use assets
7,389,000 US dollars
Property and equipment, net
2,464,000 US dollars
Accrued collaboration expenses
105,821,000 US dollars
Accrued expenses
57,699,000 US dollars
Other current liabilities
20,257,000 US dollars
Accounts payable
4,109,000 US dollars
Operating lease liabilities
3,969,000 US dollars
Other long-term liabilities
45,469,000 US dollars
Non-current deferred revenue
31,811,000 US dollars
Non-current operating lease liabilities
3,915,000 US dollars
Additional paid-in capital
1,079,688,000 US dollars
Ordinary shares value - Class A ordinary shares
12,000 US dollars
Ordinary shares value - Class A1 ordinary shares
4,000 US dollars
Ordinary shares value - Class B1 ordinary shares
4,000 US dollars
Ordinary shares value - Class B ordinary shares
1,000 US dollars
Accumulated deficit
negative 366,769,000 US dollars
Accumulated other comprehensive loss
negative 2,747,000 US dollars

Chart connections

  • Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
  • Treasury shares and other negative equity contributions reduce equity.
Kiniksa Pharmaceuticals International, plc (KNSA) FY2026 Q3 Balance Sheet Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!